Marius E Mayerhoefer1,2, Anton Staudenherz3, Barbara Kiesewetter4, Michael Weber5, Ingrid Simonitsch-Klupp6, Peter Gibbs7, Werner Dolak8, Julius Lukas9, Markus Raderer4. 1. Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. marius.mayerhoefer@meduniwien.ac.at. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. marius.mayerhoefer@meduniwien.ac.at. 3. Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. 4. Department of Medicine I, Medical University of Vienna, Vienna, Austria. 5. Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. 6. Institute of Pathology, Medical University Vienna, Vienna, Austria. 7. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 8. Department of Medicine III, Medical University of Vienna, Vienna, Austria. 9. Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Abstract
PURPOSE: Standardized uptake values (SUV), total metabolic tumor volumes (TMTV), and total lesion glycolysis (TLG) based on positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG/positron emission tomography (PET) are established outcome predictors in FDG-avid lymphomas. We therefore investigated whether these biomarkers also have prognostic value in extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma), with a focus on patients treated with anti-CD20 antibody-based immunotherapy. PROCEDURES: Pre-therapeutic [18F]FDG/PET scans of 61 treatment-naïve MALT lymphoma patients, including 35 scheduled for anti-CD20 antibody-based immunotherapy, were included in this retrospective study. SUVmean, SUVmax, TMTV, and TLG were measured and tested for 2-year progression-free survival (PFS) prognostication, using Cox regression analyses. Receiver operating characteristic curves were used to determine optimal cutoffs for prognostic [18F]FDG/PET parameters, and Kaplan-Meier estimates with log rank tests were performed. RESULTS: After 2 years, progression had occurred in 12/61 patients (CD20-anitbody group 6/35). TLG emerged as the only significant prognostic factor for 2-year PFS in the multivariate analyses with forward selection, both in entire cohort (hazard ratio HR, 1.001; 95 % CI, 1.001-1.002; P < 0.0001) and in the CD20-antibody group (HR, 1.001; 95 % CI, 1.001-1.002; P = 0.001). However, in the entire population, where 8/26 patients with a TLG > 90 (30.8 %) vs. 4/35 patients with a TLG ≤ 90 (11.4 %) showed progression within the 2-year observation period, TLG-based separation of risk groups failed (HR, 0.35; 95 % CI, 0.10-1.15; P = 0.069); whereas in the CD20-antibody group, where 6/16 patients with a TLG > 90 (37.5 %) vs. 0/19 patients with a TLG ≤ 90 (0.0 %) showed progression, risk group separation was successful (HR, 0.010; 95 % CI, 0.0001-8.068; P = 0.003). CONCLUSIONS: TLG may improve early risk stratification of MALT lymphoma patients treated with CD20-antibody-based immunotherapy.
PURPOSE: Standardized uptake values (SUV), total metabolic tumor volumes (TMTV), and total lesion glycolysis (TLG) based on positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG/positron emission tomography (PET) are established outcome predictors in FDG-avid lymphomas. We therefore investigated whether these biomarkers also have prognostic value in extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma), with a focus on patients treated with anti-CD20 antibody-based immunotherapy. PROCEDURES: Pre-therapeutic [18F]FDG/PET scans of 61 treatment-naïve MALT lymphomapatients, including 35 scheduled for anti-CD20 antibody-based immunotherapy, were included in this retrospective study. SUVmean, SUVmax, TMTV, and TLG were measured and tested for 2-year progression-free survival (PFS) prognostication, using Cox regression analyses. Receiver operating characteristic curves were used to determine optimal cutoffs for prognostic [18F]FDG/PET parameters, and Kaplan-Meier estimates with log rank tests were performed. RESULTS: After 2 years, progression had occurred in 12/61 patients (CD20-anitbody group 6/35). TLG emerged as the only significant prognostic factor for 2-year PFS in the multivariate analyses with forward selection, both in entire cohort (hazard ratio HR, 1.001; 95 % CI, 1.001-1.002; P < 0.0001) and in the CD20-antibody group (HR, 1.001; 95 % CI, 1.001-1.002; P = 0.001). However, in the entire population, where 8/26 patients with a TLG > 90 (30.8 %) vs. 4/35 patients with a TLG ≤ 90 (11.4 %) showed progression within the 2-year observation period, TLG-based separation of risk groups failed (HR, 0.35; 95 % CI, 0.10-1.15; P = 0.069); whereas in the CD20-antibody group, where 6/16 patients with a TLG > 90 (37.5 %) vs. 0/19 patients with a TLG ≤ 90 (0.0 %) showed progression, risk group separation was successful (HR, 0.010; 95 % CI, 0.0001-8.068; P = 0.003). CONCLUSIONS:TLG may improve early risk stratification of MALT lymphomapatients treated with CD20-antibody-based immunotherapy.
Authors: Matthias Eiber; Toshiki Takei; Michael Souvatzoglou; Marius E Mayerhoefer; Sebastian Fürst; Florian C Gaertner; Denys J Loeffelbein; Ernst J Rummeny; Sibylle I Ziegler; Markus Schwaiger; Ambros J Beer Journal: J Nucl Med Date: 2013-12-05 Impact factor: 10.057
Authors: Nieves Gómez León; Roberto C Delgado-Bolton; Lourdes Del Campo Del Val; Beatriz Cabezas; Reyes Arranz; Marta García; Jimena Cannata; Saturnino González Ortega; Mª Ángeles Pérez Sáez; Begoña López-Botet; Beatriz Rodríguez-Vigil; Marta Mateo; Patrick M Colletti; Domenico Rubello; José L Carreras Journal: Clin Nucl Med Date: 2017-08 Impact factor: 7.794
Authors: Vicente F Corrales-Medina; Robert A deKemp; Julio A Chirinos; Wanzhen Zeng; Jerry Wang; Grant Waterer; Rob S B Beanlands; Girish Dwivedi Journal: Chest Date: 2021-03-03 Impact factor: 10.262
Authors: Marius E Mayerhoefer; Stephen J Archibald; Christina Messiou; Anton Staudenherz; Dominik Berzaczy; Heiko Schöder Journal: J Magn Reson Imaging Date: 2019-07-01 Impact factor: 4.813